Understand the source comparison
Does Glutathione Help Liver Health Research: Formulation Comparison
The following table compares glutathione delivery methods based on bioavailability, hepatic uptake kinetics, and practical application in liver health research. Oral Free Glutathione (capsules) <5%. Degraded by GGT and peptidases in GI tract No measurable incr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares glutathione delivery methods based on bioavailability, hepatic uptake kinetics, and practical application in liver health research.
- Oral Free Glutathione (capsules)
- <5%. Degraded by GGT and peptidases in GI tract
- No measurable increase above baseline
- Negligible. Intact peptide does not reach portal circulation
- Low. Multiple studies show no plasma GSH increase
- Not recommended for therapeutic liver protocols. Functions only as amino acid source
- Liposomal Oral Glutathione
- 25–40%. Phospholipid encapsulation protects from degradation
- 0.8–1.4 mM at 90–120 minutes post-dose
- Moderate. Absorbed enterocytes release GSH into portal blood
- Moderate. Several RCTs show 20–38% plasma GSH increase
- Best oral option for hepatic glutathione repletion. Requires consistent daily dosing
- N-Acetylcysteine (NAC). Precursor
- 40–60% absorbed as cysteine
- Not applicable. Provides substrate, not intact GSH
- High. Hepatocytes preferentially uptake cysteine for de novo synthesis
- High. Extensive RCT evidence in NAFLD, acetaminophen toxicity, contrast nephropathy
- Reliable precursor strategy. Slower onset (4–6 hours) but sustains endogenous production
- Intravenous (IV) Glutathione
- 100%. Direct vascular delivery
- 1.2–2.4 mM at 15 minutes post-injection
- Very high. First-pass hepatic extraction captures 30–40% of circulating GSH
- Moderate. Several trials in NAFLD, hepatitis C, cirrhosis show enzyme normalization
- Gold standard for acute hepatoprotection and research. Requires clinical administration
- Subcutaneous Injection
- 70–85%. Slower lymphatic absorption than IV
- 0.6–1.1 mM at 60 minutes post-injection
- High. Sustained release maintains hepatic GSH availability 4–6 hours
- Low. Limited published data; primarily used in research settings
- Viable alternative to IV for sustained delivery. Self-administration feasible in research protocols
- For research applications requiring reproducible hepatic glutathione elevation, liposomal oral formulations or IV administration provide the most consistent results. NAC offers a cost-effective precursor approach when direct glutathione measurement is not required, though onset of hepatoprotective effects lags by several hours compared to intact glutathione delivery.